
Stereotaxis (STXS) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Stereotaxis in October 2026.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters.
Stereotaxis (STXS) Stock Forecast
Analyst price target, next 12 months
$3.86
+274.5% vs today's $1.03
Price range over the last 12 months
Close to its 12-month low
Analysts covering Stereotaxis have a consensus 12-month target of $3.86, above the current price of $1.03.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Stereotaxis' stock with a target price of $3.86, indicating growth potential.
Financial Health
Stereotaxis is generating steady revenue and cash flow, but overall performance is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring STXS
Boston Scientific Penumbra Deal (Cardiovascular M&A)
Boston Scientific is set to acquire Penumbra for $14.5 billion, marking a significant expansion into the high-growth thrombectomy and neurovascular device markets. This major consolidation could catalyze further M&A activity, creating investment opportunities among other innovative companies in the cardiovascular sector.
Published: 17 January 2026
Explore BasketWhy invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.